Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Formoterol in clinical practice--safety issues.

K F Rabe1

  • 1Department of Pulmonology, Leiden University Medical Center, The Netherlands. krabe@pulmonology.azl.nl

Respiratory Medicine
|September 6, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

scRNA-seq reveals persistent aberrant differentiation of nasal epithelium driven by TNFα and TGFβ in post-COVID syndrome.

Nature communications·2025
Same author

Increased breath naphthalene in children with asthma and wheeze of the All Age Asthma Cohort (ALLIANCE).

Journal of breath research·2023
Same author

[German S1 Guideline Long-/Post-COVID].

Pneumologie (Stuttgart, Germany)·2022
Same author

[Guideline for the Diagnosis and Treatment of Asthma - Addendum 2020 - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology].

Pneumologie (Stuttgart, Germany)·2021
Same author

[S2k Guideline - Recommendations for Inpatient Therapy of Patients with COVID-19].

Pneumologie (Stuttgart, Germany)·2021
Same author

[Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)].

Pneumologie (Stuttgart, Germany)·2020

Formoterol, a long-acting beta2-agonist, is well-tolerated for asthma treatment. It offers effective relief with side effects comparable to short-acting beta2-agonists, even at high doses.

Area of Science:

  • Pharmacology
  • Respiratory Medicine

Background:

  • Short-acting beta2-agonists are primary relief medication for asthma.
  • Long-acting beta2-agonists are recommended for moderate to severe asthma uncontrolled by current treatments, in combination with inhaled corticosteroids.
  • Concerns exist regarding the duration of side effects from long-acting beta2-agonists and higher doses when used as-needed.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of formoterol, a long-acting beta2-agonist.
  • To address concerns about potential side effects and tolerance with formoterol use.

Main Methods:

  • Review of studies on formoterol's efficacy and safety.
  • Comparison of formoterol's effects on serum potassium, pulse, blood pressure, cardiac frequency, and QT interval with terbutaline.

Related Experiment Videos

  • Assessment of bronchodilatory effect and tolerance during long-term formoterol use.

    • Main Results:

    • Formoterol is well tolerated, even at high doses.
    • Systemic side effects are typical of beta2-agonists but shorter in duration compared to terbutaline.
    • Formoterol demonstrated a relative therapeutic index of 2.5 compared to salbutamol.
    • No reduction in bronchodilatory effect or development of tolerance was observed with long-term use.

    Conclusions:

    • Formoterol is a well-tolerated option for asthma management.
    • Its side effect profile and duration are comparable to short-acting beta2-agonists.
    • Lack of tolerance development suggests suitability for both as-needed and regular treatment in all asthma types and severities.